Suppr超能文献

加拿大成年人中重组带状疱疹疫苗第二剂完成情况的早期观察:一项回顾性数据库研究。

An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study.

机构信息

GSK, Mississauga, Canada.

IQVIA, Ottawa, Canada.

出版信息

Vaccine. 2021 Jun 8;39(25):3397-3403. doi: 10.1016/j.vaccine.2021.04.053. Epub 2021 May 14.

Abstract

BACKGROUND

In 2017, the two-dose recombinant zoster vaccine (RZV) was authorized for use in Canada for the prevention of herpes zoster (HZ) in adults ≥ 50 years of age (YOA), which is administered 2-6 months apart. The National Advisory Committee on Immunization (NACI) states that a 0, 12-month schedule may be considered if flexibility in the timing of the second dose is needed to improve coverage. This retrospective database study evaluated the second-dose completion of RZV in Canada from January 2018 to May 2019.

METHODS

Data were obtained from the IQVIA LRx Longitudinal Prescription Database which tracks retail prescriptions of anonymized patients. Patients were followed for 6- or 12-months to evaluate the second dose completion aligned with the licensed RZV dosing schedule and NACI's option for greater flexibility. The primary outcomes were time from first to second dose and the proportion of patients who received the second dose.

RESULTS

In the 6-month (155,747 patients) and 12-month (55,524 patients) analytic cohorts, 65.0% and 74.9% received the second RZV dose within 2-6 months and 2-12 months after the first dose with a truncated mean time of 97.8 days and 109.8 days between doses, respectively. Variation in completion rates was observed across age and geography, but sex, rurality, and pharmacy type did not impact results.

CONCLUSION

Second dose completion of RZV in Canada is high but suboptimal. Further research to understand the factors influencing second dose timing and completion will be an important next step to improve series completion.

摘要

背景

2017 年,两剂重组带状疱疹疫苗(RZV)在加拿大获得批准,用于预防 50 岁及以上成年人的带状疱疹(HZ),每剂间隔 2-6 个月。国家免疫咨询委员会(NACI)指出,如果需要灵活安排第二剂的时间以提高覆盖率,也可以考虑 0、12 个月的接种时间表。本回顾性数据库研究评估了 2018 年 1 月至 2019 年 5 月期间加拿大 RZV 的第二剂接种完成情况。

方法

数据来自 IQVIA LRx 纵向处方数据库,该数据库跟踪匿名患者的零售处方。患者随访 6 或 12 个月,以评估第二剂的接种完成情况,同时考虑 RZV 许可的接种时间表和 NACI 对更大灵活性的选择。主要结局指标是第一剂到第二剂的时间以及接受第二剂的患者比例。

结果

在 6 个月(155747 例患者)和 12 个月(55524 例患者)的分析队列中,分别有 65.0%和 74.9%的患者在第一剂后 2-6 个月和 2-12 个月内接受了第二剂 RZV,平均截断时间分别为 97.8 天和 109.8 天。在不同年龄和地理区域,完成率存在差异,但性别、农村性和药房类型对结果没有影响。

结论

加拿大 RZV 的第二剂接种完成率较高,但并不理想。进一步研究影响第二剂接种时间和完成的因素,将是提高系列完成率的重要下一步。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验